National TB Control Programme

Programmatic Management of Drug Resistant Tuberculosis (PMDT) **DR TB Treatment Card** (Page 01 of 04)

Form DR TB 01

Previous Tuberculosis Treaatment History Including DR TB:

MDR TB/XDR TB/ Poly Resistance (Specify).....

Mono Resistance (Specify).....

Name of Ir	iitial Treat	tment Cer	nter:			\sqcup			on Group		Put III	K (√)	1							,	3
Address of	Initial Tre	eatment C	enter:				CAT I Non ((Remain po		nth of 2)					Na.	Start D		TB Registra			men (Write	
Father's/Husband's Name:						CAT I Failur	e (Remain p	oos. at 5 m or l	later/			No. (In Unkr			′		/ith	Regimen In Drug		Outcome	
Father's/H	usband's	Name:							e at month 2)				Yea			r) Date			Abbreviations)		
Mother's N	ame:								follow up- CAT	i			1								
Address of Patient:							CAT I Relap						-								
71001000 01						5	(Remain po	sitive at mor	nth of 3)												
Mobile No:							CAT II Failu		onth/Negative	nationt]								
Sex: □ N		positive at r		ionin/ivegative	patient																
Initial Weig		-		(cm):					ollow up- CAT	11]								
DR TB Re			_			8	CAT II Rela	pse								Outco	me.			DrugAbbr	oviations:
	-					9	Transfer in									Outc		Date	e		
	Date of DR TB Registration								atment initiation	,						Cured				First line	drugs
Date of DR TB Treatment Started://						\rightarrow	Close Conta		Unknown History	New	+		Treated		Completed			H = Isoniazi			
e-TB Manager Number						**	HIV infected	<u>'</u>	n TB S/S	Unknown History	New	Pre	eviously	Treated	Died				R = Rifampi E = Ethamb		
Site: 🗖 Pu	-		-			12	Others (Sp	ecify):								Faile	_			Z = Pyrazina	amide
Medical Di	agnosis C	Other than	TB				a) Pulmona	ary- Clinically	y diagnosed	ι	Unknown History	New	_		/ Treated					S = Streptor	nycin
History of (Contact W	ith TB/DF	R TB Patie	nts: Yes	/ No		b) Extra Pul	lmonary		l l	Unknown History	New	Pre	eviously	Treated		o follow up			Second I	ine drugs
Relation and Duration (If yes):							c) Pulmona	ry-Bacteriolo	ned	Unknown History	New				Trans	ferred out			Km = Kanamycin Ofx = Ofloxacin		
		\		eferral to the	he Local	Tre	atment/D	OTS Ce	entre:											Lfx= Levoflo	
																				Eto = Ethion	
Standardiz																				Cs = Cyclose PAS= Para-a	
Standardiz	ed XDRT	B Regime	n: Intensiv	e Phase: 0	Cm-Z-Mfx	-PA	\S-Cs-An	nx/Clv-Lz	d-Cfz Con	ntinuatio	on phase : Z	-Mfx-PA	S-C	Cs-An	nx/Clv-L	zd-Cfz	:			Acid	
			ve Phase					Cont	inuation pl	hase:										Cm=Capreo	mycin
Regimen an	d Drug Dos	es																		Clf=Clofazim	
*Date	Z (mg)	Km (mg)	Ofx/Lfx (mg)	Eto (mg)	Cs (mg)		Cm PAS Clf Amx (mg) (mg) (m					Lzd (mg)			Other	r Comments		Lzd= Linezolid Trd= Terizidone			
	(IIIg)	(mg)	(IIIg)	(IIIg)	(iiig)	-	(IIIg)	(IIIg)	(IIIg)	(mg)	(mg)	(ilig)		(11	19)					Amx/Clv= Ar	
						_														Clavulanate Mfx= Moxiflo	
														_						Other	
* Date treatme	nt started and	d doses, Chan	ge of doses (i	f any)																	
													_								
Signature of	the Division	nal PMDT C	oordinator/A	authoriry of t	he DR TB	Trea	tment Initi	ation Cent	re				Ty	ype of	Resistan	ce:					

Name and Designation:

Contact Number:

DR TB Treatment Card (Page 02 of 04)

Microscopy Results:

Month #	Week		Sputum Smear Microscopy									mear Microscopy	Month # Sputum Smear Microscopy							
		Date	e of sampl	le	Lab ID.	Date of	e of report	Result		Date of samp	e Lab ID.	Date of report	Result	Month #	D					
			ection			receive	ed T			collection	240 12	received	1100011		Date of sample collection	Lab ID.	Date of	report	Result	
0									21						collection		receive	d		
	1			i					22					-						
1	2								23											
	3								24					-			-			
	4																			
	1													Month #		Cultur	re Results		ı	
2	2									(ulture Re	sults			Date of sample		Date of	report	Result	
_	3	_						Month #	Date of samp	le Lab ID	Date of report	Result		collection	Lao ID.	receive	d	Result		
	4									collection	Lauri	received 1								
	1	_							0											
3	2	_							1											
	3	-							2											
4	4			-					3											
5									4					Common	ts on Post Tre	otmont l	Follow Un			
									5							aument	ronow-Cp	•		
6				-					6					Relaps	e Yes□	N	0 🗆	Unkno	own 🗆	
8									7					_			_			
9				-					8		+									
10									9				-	Otners:		• • • • • • • • • • • • • • • • • • • •				
11				1						ļ					Advers	se Drug R	eaction			
12				- t					11				-		Advers		Suspected			
13				1					13	1			 	Date	Drug Reac		Drugs	Me	easure Taken	
14				- t					14	<u> </u>	+		1		Drug Keac	поп	Drugs	+		
15				İ					15											
16									18											
17									21											
18									24											
19																				
20																				
Drug Susce	antihilit	Toot (DCT) Da	aultar																
*Method	Date	S	Н	R	Е	Km	Ofx/Lf	x Eto	Other	Other	Other	Notation symbol for	» DCT·							
												Notation symbol for DST:								
												R = resistant								
												S = susceptible								
1 1												C = contaminated								
*Method: 1)	Xnert N	/TR/RI	F 2) Line	Probe	Accay (I	PA) 3) I i	anid Cul	ture 4) Sol	lid culture(I	-D										
wicthod. 1)	Apertiv	TID/KI	1 2) Line	11000	Assay (L	(A) 3) Li	quiu Cui	ture +) 50	na cunture(1	3)										
Meeting Da	tes and	Decisio	ons of Cli	nical N	/Janagem	ent/PMD	T Comn	nittee:												
Date		T					cision					Next da	te							
Date						Da	2151011					1 Text da								
														HIV St	atus:					
		-												Date:						

Pos 🔲

Neg 🔲

Unknown

DR TB Treatment Card (Page 03 of 04)

Administration of Drugs (one row per month):

Form DR TB 01

Patient's Name: Month/Year 26 27 30 31 Weight (kg).

Mark in the boxes : ☐ = directly observed ☐ = not supervised ☐ = drugs not taken

DR TB Treatment Card (Page 04 of 04)

${\bf Laboratory\ and\ Radiological\ Investigation:}$

Patient's Name.....

Name and Signature of Assigned Authority of DOTS Center

Date:

Month	Date	Chast V ray	Hb(g/dl)	ESR	Blood Glucose	Serum Bilirubin	SGPT	Alkaline	Serum Creatinine	Serum	TSH	Pregnancy	Others		
		Chest X-ray						Phosphate		Potasium	1311	Test	(Specify)	(Specify)	
		-													
250															
ne of DO	I' Provider	· :	•••••	•••••	•••••	•••••	•••••		Remark	s:					
ignation :															
anization	:														
	•••••	•••••	• • • • • • • • • • • • • • • • • • • •	• • • • • • • • • • • • • • • • • • • •	•••••	•••••	•••••	• • • • • • • • • • • • • • • • • • • •							